Kancera Ab Stock Price To Earnings To Growth
Kancera AB fundamentals help investors to digest information that contributes to Kancera AB's financial success or failures. It also enables traders to predict the movement of Kancera Stock. The fundamental analysis module provides a way to measure Kancera AB's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Kancera AB stock.
Kancera |
Kancera AB Company Price To Earnings To Growth Analysis
Kancera AB's PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.
Generally speaking, PEG ratio is a 'quick and dirty' way to measure how the current price of a firm's stock relates to its earnings and growth rate. The main benefit of using PEG ratio is that investors can compare the relative valuations of companies within different industries without analyzing their P/E ratios.
CompetitionBased on the latest financial disclosure, Kancera AB has a Price To Earnings To Growth of 0.0 times. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Biotechnology industry. The price to earnings to growth for all Sweden stocks is 100.0% higher than that of the company.
Did you try this?
Run Bollinger Bands Now
Bollinger BandsUse Bollinger Bands indicator to analyze target price for a given investing horizon |
| All Next | Launch Module |
Kancera Fundamentals
| Return On Equity | -0.47 | |||
| Return On Asset | -0.27 | |||
| Operating Margin | (72.39) % | |||
| Current Valuation | 14.76 M | |||
| Shares Outstanding | 79.53 M | |||
| Shares Owned By Insiders | 13.72 % | |||
| Shares Owned By Institutions | 2.86 % | |||
| Price To Earning | (11.64) X | |||
| Price To Book | 1.44 X | |||
| Price To Sales | 168.19 X | |||
| Revenue | 1.7 M | |||
| Gross Profit | 1.7 M | |||
| EBITDA | (45.35 M) | |||
| Net Income | (45.69 M) | |||
| Cash And Equivalents | 106.52 M | |||
| Cash Per Share | 0.08 X | |||
| Total Debt | 442 K | |||
| Debt To Equity | 33.30 % | |||
| Current Ratio | 2.11 X | |||
| Book Value Per Share | 1.50 X | |||
| Cash Flow From Operations | (44.12 M) | |||
| Earnings Per Share | (0.87) X | |||
| Target Price | 1.6 | |||
| Beta | 1.28 | |||
| Market Capitalization | 262.69 M | |||
| Total Asset | 133.64 M | |||
| Working Capital | 11 M | |||
| Current Asset | 16 M | |||
| Current Liabilities | 5 M | |||
| Net Asset | 133.64 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Kancera Stock Analysis
When running Kancera AB's price analysis, check to measure Kancera AB's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kancera AB is operating at the current time. Most of Kancera AB's value examination focuses on studying past and present price action to predict the probability of Kancera AB's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kancera AB's price. Additionally, you may evaluate how the addition of Kancera AB to your portfolios can decrease your overall portfolio volatility.